These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 17257454)
1. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454 [TBL] [Abstract][Full Text] [Related]
2. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073 [TBL] [Abstract][Full Text] [Related]
3. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116 [TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Shih V; Wan HS; Chan A Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. López-Jiménez J; Martín-Ballesteros E; Sureda A; Uralburu C; Lorenzo I; del Campo R; Fernández C; Calbacho M; García-Belmonte D; Fernández G Haematologica; 2006 Jan; 91(1):84-91. PubMed ID: 16434375 [TBL] [Abstract][Full Text] [Related]
6. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489 [TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369 [TBL] [Abstract][Full Text] [Related]
8. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M; Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876 [TBL] [Abstract][Full Text] [Related]
9. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. Craver C; Gayle J; Balu S; Buchner D J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674 [TBL] [Abstract][Full Text] [Related]
10. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263 [TBL] [Abstract][Full Text] [Related]
14. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. Decker GM; DeMeyer ES; Kisko DL J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851 [TBL] [Abstract][Full Text] [Related]
15. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175 [TBL] [Abstract][Full Text] [Related]
16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S; Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083 [TBL] [Abstract][Full Text] [Related]
17. Acute and delayed nausea and emesis control in pediatric oncology patients. Holdsworth MT; Raisch DW; Frost J Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740 [TBL] [Abstract][Full Text] [Related]
18. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Rogers MP; Blackburn L Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. Booth CM; Clemons M; Dranitsaris G; Joy A; Young S; Callaghan W; Trudeau M; Petrella T J Support Oncol; 2007 Sep; 5(8):374-80. PubMed ID: 17944146 [TBL] [Abstract][Full Text] [Related]
20. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]